Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: A multimodality approach for locally advanced breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 2, 2011, Pages 221-228

  Kountourakis, Panteleimon ^a   Missitzis, Ioannis ^a   Doufexis, Dimitrios ^a   Zobolas, Vassileios ^a   Pissakas, Georgios ^a   Arnogiannaki, Niki ^a   Maliou, Savoula ^a   Sotiropoulou, Anastasia ^a   Ardavanis, Alexandros ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Locally advanced breast cancer; Multimodality treatment; Prognosis; Tumor response

Indexed keywords

DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FAMOTIDINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LUTEINIZING HORMONE; NAVELBINE; ONDANSETRON; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASPIRATION BIOPSY; BLOOD TOXICITY; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLIMACTERIUM; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHLEBITIS; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PREMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SENSORY DYSFUNCTION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 78751611596     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0878-8     Document Type: Article

References (22)

1. A Ardavanis A Scorilas D Tryfonopoulos, et al. 2006 Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results Oncologist 11 6 563 573 1:CAS:528:DC%2BD28XhtFGhu7vJ 10.1634/theoncologist.11-6-563 16794236 (Pubitemid 43967612)
2. A Ardavanis P Kountourakis S Maliou, et al. 2007 Gemcitabine and oral vinorelbine as salvage treatment in patients with advanced anthracycline- and taxane-pretreated breast cancer Anticancer Res 27 4C 2989 2992 1:CAS:528:DC%2BD2sXpvFChtbs%3D 17695483
3. HD Bear S Anderson RE Smith, et al. 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27 J Clin Oncol 24 13 2019 2027 1:CAS:528:DC%2BD28Xlt1amur0%3D 10.1200/JCO.2005.04.1665 16606972 (Pubitemid 46622110)
4. H Bonnefoi S Diebold-Berger P Therasse, et al. 2003 Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5 year clinical outcome? Ann Oncol 14 406 413 1:STN:280: DC%2BD3s%2Fos1Gmtw%3D%3D 10.1093/annonc/mdg108 12598346 (Pubitemid 36367418)
5. Buzdar AU, Valero V, Theriault RL et al (2003) Pathological complete response to chemotherapy is related to hormone receptor status [abstract]. In: 26th San Antonio Breast Cancer Symposium Abstr. 302. Breast Cancer Res Treat, vol 85, p 2
6. SD Costa S Loibl M Kaufmann, et al. 2010 Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio Trial Data J Clin Oncol 28 83 91 1:CAS:528:DC%2BC3cXhtF2rsrw%3D 10.1200/JCO.2009.23.5101 19901111
7. M Donadio M Ardine A Berruti, et al. 2003 Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study Cancer Chemother Pharmacol 52 2 147 152 1:CAS:528:DC%2BD3sXlsVylsbo%3D 10.1007/s00280-003-0632-x 12764672 (Pubitemid 37041348)
8. B Fisher J Bryant N Wolmark, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 2672 2685 1:CAS:528:DyaK1cXlsFCgurg%3D 9704717
9. P Fumoleau FM Delgado T Delozier, et al. 1993 Phase II trial of weekly intravenous vinorelbine as first line advanced breast cancer chemotherapy J Clin Oncol 11 7 1245 1252 1:STN:280:DyaK3szgtFKmtQ%3D%3D 8315421
10. HS Giordano 2003 Update on locally advanced breast cancer Oncologist 8 521 530 10.1634/theoncologist.8-6-521 14657530 (Pubitemid 37467367)
11. V Guarneri K Broglio SW Kau, et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 7 1037 1044 10.1200/JCO.2005.02.6914 16505422 (Pubitemid 46638799)
12. IA Jaiyesimi AU Buzdar NG Hortobagyi 1992 Inflammatory breast cancer: a review J Clin Oncol 10 1014 1024 1:STN:280:DyaK383mvV2gtQ%3D%3D 1588366
13. HM Kuerer LA Newman TL Smith, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2 460 469 1:CAS:528:DyaK1MXht1Wmur4%3D 10080586
14. JA Low AW Berman SM Steinberg, et al. 2004 Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy J Clin Oncol 22 20 4067 4074 1:CAS:528: DC%2BD2cXpslOrsro%3D 10.1200/JCO.2004.04.068 15483018 (Pubitemid 41185175)
15. National Cancer Institute, DCCPS, Surveilance Research Program Cancer Statistics Branch (2001). SEER Program Public Use Data Tapes 1973-1998
16. Rha SY, Moon YH, Jeung HC et al (2005) Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90(3):215-221
17. P Rastogi SJ Anderson HD Bear, et al. 2008 Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 5 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
18. SE Singletary C Allred P Ashley, et al. 2002 Revision of the American Joint Committee on Cancer staging system for breast cancer J Clin Oncol 20 3628 3636 10.1200/JCO.2002.02.026 12202663 (Pubitemid 34983222)
19. IC Smith SD Heys AW Hutcheon, et al. 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 6 1456 1466 1:CAS:528:DC%2BD38XivFeisbg%3D 10.1200/JCO.20.6.1456 11896092 (Pubitemid 34260523)
20. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
21. G von Minckwitz G Raab A Caputo, et al. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 12 2676 2685 10.1200/JCO.2005.05.078 (Pubitemid 46179457)
22. BL Weber C Vogel S Jones, et al. 1995 Intravenous vinorelbine as first line and second line therapy in advanced breast cancer J Clin Oncol 13 11 2722 2730 1:CAS:528:DyaK28XitlGmtA%3D%3D 7595730